Risk adjusted net present value: What is the current valuation of Biomea Fusion’s Icovamenib?

Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.

PacBio announces HiFi Solves, a global consortium of clinical genomics research leaders

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the HiFi Solves consortium.

November 2, 2023

Turnstone Biologics rides biotech’s IPO train in Friday debut

Turnstone Biologics raised $80 million in a Friday morning IPO under the ticker $TSBX, bookending a rare two-week stretch for biotech listings. The startup follows

July 22, 2023

Prenatal air pollution exposure linked to adolescent mental health problems

A baby’s exposure to air pollution while in the womb is associated with the development of certain mental health problems once the infant reaches adolescence,

May 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.